Brief of diving:
- Eli Lilly said he will build a 6.5 billion dollars of factory In Houston he focused on the manufacture of the first obesity pill of the company and other medicines of small molecules.
- The 236-hectare site will produce active pharmaceutical ingredients, including Orforglpron, a small agonist of the GLP-1 oral receiver, according to a statement. The agonist of the molecule is up to the regulatory consideration later this year.
- Located in Generation Park, the factory will create 615 full -time jobs for the area, such as engineers, scientists and laboratory technicians, according to the Greater Houston Partnership. Construction is expected to end in the next five years.
Divide vision:
The Houston installation is the second of four north -American -American manufacturing sites, this year is planning to present this year as part of a greater commitment to strengthen domestic medicine production.
The first location It was announced last week and is scheduled for Goochland County, outside Richmond, Virginia. This $ 5 billion installation will cause the ingredients to be used in cancer and autoimmune treatments.
Like the Virginia project, Lilly’s Houston installation receives state support. It has been approved for a dollars Fund Texas Fund grant by Virtue of the Texas Jobs, Energy, Technology and Innovation program. The biopharmaceutical project is one of the first to be approved in the new Texas program.
“ Our new Houston site will improve Lilly’s ability to manufacture Orforglprgron on a scale and, if approved, will help fulfill the potential of medicine as a metabolic health treatment for tens of millions of people around the world, ” said Lilly’s CEO David Ricks in a statement.
Lilly at the beginning of the year pledged to invest more than $ 50 billion to build and reform Its North -American factories as a way to remodel “the critical capabilities of the chemical synthesis of small molecules”. In total, the company hopes that its four factories will use more than 3,000 technicians, scientists and other staff, as well as support 10,000 construction jobs. Lilly plans to reveal the locations and other details about his two north -American floors this year.
“The Lilly project represents one of the largest life science investments in the history of Texas and is a powerful endorsement of Houston’s growing position as a global center for innovation, advanced manufacture and biomedical excellence,” said Steve Kean, CEO of Greater Partnership, Steve Kean.
Lilly considered more than 300 competing locations before deciding on Houston for his next manufacturing facility. The company said that it evaluated factors such as the potential of labor, local incentives, access to public services and transport, as well as the business environment.
Lilly plans to take advantage of digital automation at Houston’s installation, such as automatic learning, artificial intelligence and advanced analytics. In order to guarantee a strong talent of talent, the company said it will collaborate with local universities and will invest in educational initiatives throughout Texas.
The San Jacinto College is expected to open the Biotechnology Center, an effort to develop labor, on its generation park campus at the end of this month. The center will be the only certified supplier of the National Institute of Bioprocessing Research and Training in the south of the United States, according to Houston’s majority.
In addition to the jobs of the facilities, the Houston project is expected to support 4,000 construction jobs. Lilly estimated that for each inverted dollar, the local economy will generate up to four dollars.
The 150 -year -old pharmaceutical giant has more than 49,000 employees worldwide, with almost half based in the United States. Its domestic manufacturing facilities are in Indiana, North Carolina, New Jersey, Wisconsin and Puerto Rico.
